Characterisation of Immunoparesis in Newly Diagnosed Myeloma and Its Impact on Progression-free and Overall Survival in Both Old and Recent Myeloma Trials

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2018 Jun 22

PMID 29925902

Citations 33

Authors

Jennifer L J Heaney

John P Campbell

Gulnaz Iqbal

David Cairns

Alex Richter

J Anthony Child

Walter Gregory

Graham Jackson

Martin Kaiser

Roger Owen

Faith Davies

Gareth Morgan

Janet Dunn

Mark T Drayson

Affiliations

Soon will be listed here.

Abstract

We measured immunosuppression at myeloma diagnosis and assessed the impact on survival in 5826 UK myeloma trial patients. Polyclonal immunoglobulin levels were below normal in 85% of patients and above normal in only 0.4% of cases for IgA, 0.2% for IgM and no cases for IgG. Immunoparesis had a greater impact in recent trials: median overall survival (OS) was up to 3 years longer for patients without immunoparesis compared to the old trials, less than 1 year longer. Median progression-free survival (PFS) was 39%, 36% and 57% longer for patients with normal IgG, IgA and IgM levels, respectively. The depth of IgM suppression, but not the depth of IgG or IgA suppression, was prognostic for survival: the most severely suppressed IgM tertile of patients OS was 0.9 years shorter than those in the top tertile, and 2.6 years shorter than OS of those with normal IgM levels (p = .007). The degree of suppression of polyclonal IgM levels below normal was associated with worse PFS (p = .0002). Infection does not appear to be the main mechanism through which immunoparesis affects survival. We hypothesise that IgM immunoparesis impacts through a combination of being associated with more aggressive disease and reduced immune surveillance against relapse.

Citing Articles

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

Lakhwani S, Mateos M, Martinez-Lopez J, Paiva B, Rosinol Dachs L, Martinez R Ann Hematol. 2024; 103(12):5651-5661.

PMID: 39438321 DOI: 10.1007/s00277-024-06031-0.

Immunoglobulin Replacement Therapy: Insights into Multiple Myeloma Management.

Saltarella I, Altamura C, Solimando A, DAmore S, Ria R, Vacca A Cancers (Basel). 2024; 16(18).

PMID: 39335161 PMC: 11430154. DOI: 10.3390/cancers16183190.

Navigating the clinical landscape: Update on the diagnostic and prognostic biomarkers in multiple myeloma.

Raghunathachar S, Krishnamurthy K, Gopalaiah L, Abhijith D, Prashant A, Parichay S Mol Biol Rep. 2024; 51(1):972.

PMID: 39249557 DOI: 10.1007/s11033-024-09892-w.

Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms.

Faustini S, Chan Y, Evans L, Collman E, Rapson A, Backhouse C Leukemia. 2024; 38(11):2501-2504.

PMID: 39244631 PMC: 11519000. DOI: 10.1038/s41375-024-02398-1.

Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis.

Mahmud S, Hossain M, Muyeed A, Nazneen S, Haque M, Mazumder H PLoS One. 2024; 19(9):e0308463.

PMID: 39241024 PMC: 11379232. DOI: 10.1371/journal.pone.0308463.

References

Katzmann J, Clark R, Abraham R, Bryant S, Lymp J, Bradwell A . Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002; 48(9):1437-44. View

Rajkumar S, Landgren O, Mateos M . Smoldering multiple myeloma. Blood. 2015; 125(20):3069-75. PMC: 4432003. DOI: 10.1182/blood-2014-09-568899. View

Pruzanski W, Gidon M, Roy A . Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis. Clin Immunol Immunopathol. 1980; 17(2):280-6. DOI: 10.1016/0090-1229(80)90097-5. View

Morgan G, Davies F, Gregory W, Bell S, Szubert A, Navarro Coy N . Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2011; 97(3):442-50. PMC: 3291601. DOI: 10.3324/haematol.2011.043372. View

Wangel A . Multiple myeloma and polyclonal hypogammaglobulinaemia. Acta Med Scand. 1987; 221(5):421-5. DOI: 10.1111/j.0954-6820.1987.tb01275.x. View

Perez-Persona E, Vidriales M, Mateo G, Garcia-Sanz R, Mateos M, Garcia de Coca A . New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007; 110(7):2586-92. DOI: 10.1182/blood-2007-05-088443. View

Rajkumar S, Harousseau J, Durie B, Anderson K, Dimopoulos M, Kyle R . Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-5. PMC: 3710442. DOI: 10.1182/blood-2010-10-299487. View

Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S . Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977; 35(1):1-39. PMC: 2025310. DOI: 10.1038/bjc.1977.1. View

Morgan G, Davies F, Gregory W, Cocks K, Bell S, Szubert A . First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010; 376(9757):1989-99. PMC: 3639680. DOI: 10.1016/S0140-6736(10)62051-X. View

10.

Kyle R, Gertz M, Witzig T, Lust J, Lacy M, Dispenzieri A . Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78(1):21-33. DOI: 10.4065/78.1.21. View

11.

Morgan G, Davies F, Gregory W, Russell N, Bell S, Szubert A . Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011; 118(5):1231-8. PMC: 3152492. DOI: 10.1182/blood-2011-02-338665. View

12.

Augustson B, Begum G, Dunn J, Barth N, Davies F, Morgan G . Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005; 23(36):9219-26. DOI: 10.1200/JCO.2005.03.2086. View

13.

Pratt G, Goodyear O, Moss P . Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007; 138(5):563-79. DOI: 10.1111/j.1365-2141.2007.06705.x. View

14.

Sorrig R, Klausen T, Salomo M, Vangsted A, Ostergaard B, Gregersen H . Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. Eur J Haematol. 2015; 97(3):303-9. DOI: 10.1111/ejh.12728. View

15.

Kawano M, Iwato K, Asaoku H, TANABE O, Tanaka H, Ishikawa H . Altered cytokine activities are related to the suppression of synthesis of normal immunoglobulin in multiple myeloma. Am J Hematol. 1989; 30(2):91-6. DOI: 10.1002/ajh.2830300208. View

16.

Blimark C, Holmberg E, Mellqvist U, Landgren O, Bjorkholm M, Hultcrantz M . Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2014; 100(1):107-13. PMC: 4281323. DOI: 10.3324/haematol.2014.107714. View

17.

Morgan G, Gregory W, Davies F, Bell S, Szubert A, Brown J . The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2011; 119(1):7-15. DOI: 10.1182/blood-2011-06-357038. View

18.

Gonzalez-Calle V, Cerda S, Labrador J, Sobejano E, Gonzalez-Mena B, Aguilera C . Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica. 2017; 102(5):922-931. PMC: 5477611. DOI: 10.3324/haematol.2016.158345. View

19.

Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A . Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia. 2014; 28(10):2075-9. DOI: 10.1038/leu.2014.110. View

20.

Nucci M, Anaissie E . Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009; 49(8):1211-25. DOI: 10.1086/605664. View